JP2017501202A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501202A5
JP2017501202A5 JP2016544410A JP2016544410A JP2017501202A5 JP 2017501202 A5 JP2017501202 A5 JP 2017501202A5 JP 2016544410 A JP2016544410 A JP 2016544410A JP 2016544410 A JP2016544410 A JP 2016544410A JP 2017501202 A5 JP2017501202 A5 JP 2017501202A5
Authority
JP
Japan
Prior art keywords
nicotinamide
pyridin
cyano
fluoro
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016544410A
Other languages
English (en)
Japanese (ja)
Other versions
JP6475252B2 (ja
JP2017501202A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/010006 external-priority patent/WO2015103453A1/en
Publication of JP2017501202A publication Critical patent/JP2017501202A/ja
Publication of JP2017501202A5 publication Critical patent/JP2017501202A5/ja
Application granted granted Critical
Publication of JP6475252B2 publication Critical patent/JP6475252B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016544410A 2014-01-03 2015-01-02 ヘテロアリール置換のニコチンアミド化合物 Expired - Fee Related JP6475252B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461923403P 2014-01-03 2014-01-03
US61/923,403 2014-01-03
PCT/US2015/010006 WO2015103453A1 (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds

Publications (3)

Publication Number Publication Date
JP2017501202A JP2017501202A (ja) 2017-01-12
JP2017501202A5 true JP2017501202A5 (enExample) 2018-12-13
JP6475252B2 JP6475252B2 (ja) 2019-02-27

Family

ID=52355270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544410A Expired - Fee Related JP6475252B2 (ja) 2014-01-03 2015-01-02 ヘテロアリール置換のニコチンアミド化合物

Country Status (21)

Country Link
US (1) US9169252B2 (enExample)
EP (1) EP3089973B1 (enExample)
JP (1) JP6475252B2 (enExample)
KR (1) KR20160101191A (enExample)
CN (1) CN106061967B (enExample)
AR (1) AR098991A1 (enExample)
AU (1) AU2015204045A1 (enExample)
CA (1) CA2935329A1 (enExample)
CL (1) CL2016001706A1 (enExample)
EA (1) EA201691343A1 (enExample)
ES (1) ES2804707T3 (enExample)
IL (1) IL246474A0 (enExample)
MA (1) MA39162A1 (enExample)
MX (1) MX2016008723A (enExample)
PE (1) PE20161292A1 (enExample)
PH (1) PH12016501164A1 (enExample)
SG (1) SG11201605340QA (enExample)
TN (1) TN2016000271A1 (enExample)
TW (1) TW201609693A (enExample)
UY (1) UY35935A (enExample)
WO (1) WO2015103453A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013341200A1 (en) 2012-11-08 2015-07-02 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
CN104781251B (zh) 2012-11-08 2016-12-14 百时美施贵宝公司 可作为激酶调节剂的经双环杂环取代的吡啶基化合物
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
PL3089971T3 (pl) 2014-01-01 2021-01-25 Medivation Technologies Llc Związki i sposoby ich zastosowania
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN107849039B (zh) 2015-06-24 2020-07-03 百时美施贵宝公司 经杂芳基取代的氨基吡啶化合物
EP3313844B1 (en) * 2015-06-24 2020-08-26 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
TW201713655A (zh) 2015-06-24 2017-04-16 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
GB201518456D0 (en) 2015-10-19 2015-12-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
TW202340194A (zh) * 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CN110997670B (zh) * 2017-08-04 2022-11-01 百时美施贵宝公司 [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
MY202326A (en) 2017-09-14 2024-04-24 Daiichi Sankyo Co Ltd Compound having cyclic structure
MX2020003190A (es) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TW201927769A (zh) * 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ii
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
CA3090275A1 (en) 2018-02-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Irak degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP4010317B1 (en) 2019-08-06 2024-06-19 Bristol-Myers Squibb Company Bicyclic heterocyclic compounds useful as irak4 inhibitors
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
EP4100408B1 (en) 2020-02-03 2024-02-28 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
JP7815127B2 (ja) 2020-02-19 2026-02-17 ニューリックス セラピューティクス,インコーポレイテッド インターロイキン-1受容体関連キナーゼの二機能性分解剤およびその治療的使用
EP4161521A4 (en) 2020-06-03 2024-07-10 Kymera Therapeutics, Inc. DEUTERED IRAQ DEGRADERS AND USES THEREOF
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
AR124547A1 (es) 2020-12-30 2023-04-05 Kymera Therapeutics Inc Degradadores de irak y sus usos
WO2022174268A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
MX2023009178A (es) 2021-02-15 2023-08-21 Kymera Therapeutics Inc Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
WO2023008973A1 (ko) * 2021-07-29 2023-02-02 프라비바이오 주식회사 신규 벤젠 유도체 및 이의 면역억제 관련 용도
HUE070709T2 (hu) 2021-08-18 2025-06-28 Nurix Therapeutics Inc Interleukin-1 receptorhoz kapcsolódó kinázok kétfunkciós lebontói és terápiás alkalmazásuk
JP2024540080A (ja) 2021-10-29 2024-10-31 カイメラ セラピューティクス, インコーポレイテッド Irak4分解剤およびその合成
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses
WO2025151602A1 (en) * 2024-01-11 2025-07-17 Bristol-Myers Squibb Company Heteroaryl compounds as ligand directed degraders of irak4
WO2025151728A1 (en) * 2024-01-12 2025-07-17 Bristol-Myers Squibb Company Ligand directed degrader of irak4
CN118388401B (zh) * 2024-06-28 2024-08-20 成都凯斯坦生物医药有限公司 一种4-氨基-2-氯烟醛的制备方法
CN118641677B (zh) * 2024-08-16 2024-11-05 北京京丰制药集团有限公司 尼可刹米原料中杂质的检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
CA2450769A1 (en) 2001-06-15 2002-12-27 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
ES2373226T3 (es) 2002-06-28 2012-02-01 Astellas Pharma Inc. Derivado de diaminopirimidincarboxamida.
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
EP1651636A1 (en) 2003-07-10 2006-05-03 Neurogen Corporation Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CN101679376A (zh) 2007-06-08 2010-03-24 拜尔农科股份有限公司 杀真菌剂杂环-嘧啶基-氨基衍生物
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
KR101361027B1 (ko) * 2008-11-28 2014-02-11 코와 가부시키가이샤 피리딘-3-카르복시아미드 유도체
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
BR112012010220A2 (pt) 2009-10-30 2021-02-23 Janssen Pharmaceutical N.V. piridinas fenóxi-substituídas como modulares do receptor opioide
EP2532656A1 (en) 2010-02-01 2012-12-12 Nippon Chemiphar Co., Ltd. Gpr119 agonist
AU2012249240A1 (en) 2011-04-29 2013-11-07 Icahn School Of Medicine At Mount Sinai Kinase inhibitors
US9074384B2 (en) * 2011-07-27 2015-07-07 Intex Recreation Corp. Combined swimming pool ladder structure
EP2802579B1 (en) * 2012-01-13 2016-04-13 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
ES2686500T3 (es) 2012-01-13 2018-10-18 Bristol-Myers Squibb Company Compuestos de piridilo sustituidos con heterocíclicos, útiles como inhibidores de cinasas
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
EP2922841B8 (en) 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
AU2013341200A1 (en) * 2012-11-08 2015-07-02 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
CN104781251B (zh) 2012-11-08 2016-12-14 百时美施贵宝公司 可作为激酶调节剂的经双环杂环取代的吡啶基化合物

Similar Documents

Publication Publication Date Title
JP6475252B2 (ja) ヘテロアリール置換のニコチンアミド化合物
JP2018522859A5 (enExample)
JP7576552B2 (ja) イミダゾ[1,2-a]ピリジニル誘導体及び疾患の処置におけるその使用
CN111372931B (zh) 作为蛋白激酶抑制剂的杂环化合物
AU2010333804B2 (en) Fused heteroaromatic pyrrolidinones as syk inhibitors
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
JP6689871B2 (ja) Fgfr阻害剤としての二環式複素環
TWI911225B (zh) 治療性化合物及其用途
KR102339227B1 (ko) Gsk-3 억제제
AU2017378943A1 (en) FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
JP2016523911A5 (enExample)
AU2010335556A1 (en) Imidazopyridine derivatives as JAK inhibitors
JP2018524331A5 (enExample)
SG184822A1 (en) Fused bicyclic kinase inhibitors
RS54823B1 (sr) Derivati piperidin-4-il azetidina kao inhibitori jak1
JP2013523884A5 (enExample)
KR20190019187A (ko) 헤테로아릴 치환된 아미노피리딘 화합물
JP2022545364A5 (enExample)
JP2023510874A (ja) 置換ピラゾロ-ピリミジンおよびその使用
AU2021405620A1 (en) Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
CN107108653B (zh) 吡唑并噻唑化合物及医药
US9150592B2 (en) Heterocyclic nuclear hormone receptor modulators
WO2025017078A1 (en) New pyrazolopyridine derivatives
CA3257173A1 (en) Pyrrolidine derivatives useful as NF-κB induction kinase inhibitors
KR102133595B1 (ko) 단백질 키나제 억제제로서의 헤테로고리 화합물